Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
AIM ImmunoTech Inc (AIM)
NYSE MKT:AIM
Holding AIM?
Track your performance easily
Earnings Data
Report Date
Apr 07, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.12Last Year’s EPS
-$0.12Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 15, 2024
|% Change Since: -24.60%
|Next Earnings Date:Apr 07, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in clinical trials, particularly in pancreatic cancer and manufacturing efficiencies. However, financial disputes and ongoing activist investor challenges pose potential threats to the company's stability and future progress.Company Guidance
During the AIM ImmunoTech Q3 2024 earnings call, management provided guidance on several key metrics and developments. The company highlighted positive preliminary data from the DURIPANC Phase Ib/II study, showing promising results for Ampligen in combination with AstraZeneca's durvalumab in metastatic pancreatic cancer. They reported an 83% stable disease rate at three months for those on both 200- and 400-milligram doses, significantly higher than historical rates. Ampligen also showed potential in post-COVID fatigue, with statistically significant data supporting its efficacy in a subset of patients. Financially, AIM is negotiating $4.9 million in accounts payable and addressing a $2.5 million insurance coverage issue. Additionally, cost-saving measures in Ampligen manufacturing were outlined, potentially reducing production expenses by 60-70%. The company is also contending with activist investors seeking to replace the board, which management argues could jeopardize financial stability.Positive Clinical Trial Data
AIM ImmunoTech announced positive preliminary data from the Phase Ib/II study (DURIPANC) evaluating Ampligen in combination with AstraZeneca's durvalumab for metastatic pancreatic cancer, showing improvement in progression-free survival by 7 months compared to historical controls.
Patent Portfolio Expansion
The United States Patent and Trademark Office granted a patent for Ampligen in the treatment of endometriosis, enhancing AIM's attractiveness for partnerships or buyouts.
Manufacturing Process Improvements
Optimization of Ampligen's manufacturing process with Sterling Pharma Solutions resulted in a 40% reduction in polymer production time, saving AIM an estimated $2 million and reducing future costs by $200,000 per batch.
Scientific Publications
Publication of data analysis from the long-term early access program studying Ampligen for advanced pancreatic ductal adenocarcinoma in the Clinical Cancer Research journal.
---
AIM Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
AIM Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 15, 2024 | $0.25 | $0.22 | -12.00% |
| Aug 16, 2024 | $0.29 | $0.30 | +3.45% |
| May 16, 2024 | $0.40 | $0.39 | -2.50% |
| Apr 02, 2024 | $0.49 | $0.45 | -8.16% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does AIM ImmunoTech Inc (AIM) report earnings?
AIM ImmunoTech Inc (AIM) is schdueled to report earning on Apr 07, 2025, TBA Not Confirmed.
What is AIM ImmunoTech Inc (AIM) earnings time?
AIM ImmunoTech Inc (AIM) earnings time is at Apr 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AIM EPS forecast?
AIM EPS forecast for the fiscal quarter 2024 (Q4) is -$0.12.
---